|
García-Malo MD, Corral J, González M, Solano C, González-Conejero R, Caballero MD, Pérez R, Moraleda JM, Vicente V. Human platelet antigen systems in allogeneic peripheral blood progenitor cell transplantation: effect of human platelet antigen mismatch on platelet engraftment and graft-versus-host disease. Transfusion. 2004 May;44(5):771-6. PubMed PMID: 15104661.
AÑO: 2004; IF: 3.708
|
15104661
|
Pérez-Simón JA, Sureda A, Fernández-Aviles F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomás JF, Moraleda JM, Alegre A, Cañizo C, Brunet S, Rosiñol L, Lahuerta J, Díez-Martín JL, León A, García A, Vazquez L, Sierra J, San Miguel JF; Grupo Español de Mieloma. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006 Mar;20(3):542-5. PubMed PMID: 16408097.
AÑO: 2006; IF: 6.146
|
|
Moraleda JM, Blanquer M, Bleda P, Iniesta P, Ruiz F, Bonilla S, Cabanes C, Tabares L, Martinez S. Adult stem cell therapy: dream or reality? Transpl Immunol. 2006 Dec;17(1):74-7. Epub 2006 Oct 16. Review. PubMed PMID: 17157222.
AÑO: 2006; IF: 2.297
|
|
Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol. 2007 Apr;78(4):290-6. PubMed PMID: 17378891.
AÑO: 2007; IF: 2.163
|
|
Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008 Feb 1;26(4):577-84. Epub 2007 Dec 17. PubMed PMID: 18086801.
AÑO: 2008; IF: 17.157
|